A recent study by Li G, et al. [2022] was carried out to assess how pulmonary function has different risk magnitudes for cardiometabolic diseases [CD] and cardiometabolic multimorbidity [CM].
The Vitalograph Pneumotrac, a powerful and flexible diagnostic device suitable for testing adults and paediatrics, was used to conduct parts of the study.
The exercise concluded that “pulmonary function could be used as a valuable predictor for the tailored prevention of individual cardiometabolic diseases and CM. Stratifying different high-risk populations through pulmonary function to implement precision medicine may have far-reaching clinical implications”.
Vitalograph offers respiratory clinical trials solutions including ECG devices and expert cardiac analysis to ensure accurate endpoint data such as QT/QTc, as well as providing timely interpretations and alerts to support safety monitoring of subjects throughout clinical trials.
The full report on the study of pulmonary function in cardiometabolic endpoints can be found here.
Photo by National Cancer Institute on Unsplash